These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 18765129)

  • 1. Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Porst H; Sandner P; Ulbrich E
    Curr Urol Rep; 2008 Jul; 9(4):295-301. PubMed ID: 18765129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.
    Tinel H; Stelte-Ludwig B; Hütter J; Sandner P
    BJU Int; 2006 Dec; 98(6):1259-63. PubMed ID: 16956354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Stief CG; Porst H; Neuser D; Beneke M; Ulbrich E
    Eur Urol; 2008 Jun; 53(6):1236-44. PubMed ID: 18281145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Gacci M; Vittori G; Tosi N; Siena G; Rossetti MA; Lapini A; Vignozzi L; Serni S; Maggi M; Carini M
    J Sex Med; 2012 Jun; 9(6):1624-33. PubMed ID: 22510238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
    Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of chronic treatment with vardenafil, a phosphodiesterase 5 inhibitor, on female rat bladder in a partial bladder outlet obstruction model.
    Matsumoto S; Hanai T; Uemura H; Levin RM
    BJU Int; 2009 Apr; 103(7):987-90. PubMed ID: 19021615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vardenafil: efficacy, tolerability and future directions.
    Rice KR; Dean RC
    Expert Opin Drug Metab Toxicol; 2009 May; 5(5):553-62. PubMed ID: 19416089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [PDE5 inhibitors in treatment of benign prostatic syndrome].
    Sandner P; Tinel H; Stelte-Ludwig B; Huetter J; Neuser D; Bischoff E; Ulbrich E
    Urologe A; 2007 Sep; 46(9):1189-92. PubMed ID: 17609921
    [No Abstract]   [Full Text] [Related]  

  • 9. Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
    Gacci M; Andersson KE; Chapple C; Maggi M; Mirone V; Oelke M; Porst H; Roehrborn C; Stief C; Giuliano F
    Eur Urol; 2016 Jul; 70(1):124-133. PubMed ID: 26806655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS.
    Vignozzi L; Gacci M; Cellai I; Morelli A; Maneschi E; Comeglio P; Santi R; Filippi S; Sebastianelli A; Nesi G; Serni S; Carini M; Maggi M
    Prostate; 2013 Sep; 73(13):1391-402. PubMed ID: 23765639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?
    Roumeguère T; Zouaoui Boudjeltia K; Hauzeur C; Schulman C; Vanhaeverbeek M; Wespes E
    BJU Int; 2009 Aug; 104(4):511-7. PubMed ID: 19239452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia.
    Wang C
    Curr Opin Urol; 2010 Jan; 20(1):49-54. PubMed ID: 19887943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vardenafil can improve continence recovery after bilateral nerve sparing prostatectomy: results of a randomized, double blind, placebo-controlled pilot study.
    Gacci M; Ierardi A; Rose AD; Tazzioli S; Scapaticci E; Filippi S; Maggi M; Nicita G; Carini M; Montorsi F
    J Sex Med; 2010 Jan; 7(1 Pt 1):234-43. PubMed ID: 19732303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re: Christian G. Stief, Hartmut Porst, Dieter Neuser, et al. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008;53:1236-44.
    Gacci M; Carini M; Maggi M
    Eur Urol; 2009 Jan; 55(1):e25-6. PubMed ID: 18486304
    [No Abstract]   [Full Text] [Related]  

  • 15. Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms.
    Miller MS
    Ann Pharmacother; 2013 Feb; 47(2):278-83. PubMed ID: 23386068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of the lower urinary tract symptoms secondary to benign prostatic hyperplasia by phosphodiesterase type 5 inhibitors. Review article].
    Caremel R; Oger-Roussel S; Behr-Roussel D; Grise P; Giuliano F
    Prog Urol; 2010 Oct; 20(9):616-26. PubMed ID: 20951929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urodynamic effects of once-daily tadalafil in men with LUTS secondary to clinical BPH.
    Gomelsky A; Dmochowski RR
    Curr Urol Rep; 2010 Jul; 11(4):254-60. PubMed ID: 20480269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does sildenafil affect uroflowmetry values in men with lower urinary tract symptoms suggestive of benign prostatic enlargement?
    Güler C; Tüzel E; Doğantekin E; Kiziltepe G
    Urol Int; 2008; 80(2):181-5. PubMed ID: 18362490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
    Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
    J Urol; 2010 Mar; 183(3):1092-7. PubMed ID: 20092847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potency and selectivity of vardenafil: a phosphodiesterase Type 5 inhibitor.
    Sommer F
    Expert Opin Drug Metab Toxicol; 2005 Aug; 1(2):295-301. PubMed ID: 16922644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.